ASH 2025

Questions discussed in this category

How will you utilize the PARADIGM study results from ASH 2025, comparing azacitidine/venetoclax to intensive induction chemotherapy for fit patients with newly diagnosed AML?

Aza/ven patients had better EFS/QoL with a greater proportion of patients who successfully got to a stem cell transplant. Provided that the OS data is...

1 Answer available

After the MAJESTEC-3 results, and once approved, what is your approach to choosing between tec-dara vs. cilta-cel versus another triplet for multiple myeloma in first relapse?

4 Answers available

What is your approach to iron supplementation in patients with an active infection?

Are there situations in which you still feel comfortable giving IV iron? If not, do you consider PO iron?

1 Answer available

How does the CLL17 trial presented at ASH 2025 change current practice guidelines?

Should all CLL patients be candidates for fixed-duration treatments?

1 Answer available

Papers discussed in this category

American journal of hematology, 2024 Jan 29

Expert consensus guidelines: Intravenous iron uses, formulations, administration, and management of reactions.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2024 Jun 12

AGA Clinical Practice Update on Management of Iron Deficiency Anemia: Expert Review.

American family physician, 2022 Sep

Risk of Infection With Intravenous Iron Infusion.

Journal of the American College of Cardiology, 2024 Jun 25

Intravenous Iron Repletion for Patients With Heart Failure and Iron Deficiency: JACC State-of-the-Art Review.

N Engl J Med, 2023 Jun 05

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.

The New England journal of medicine, 2023 Dec 12

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

The New England journal of medicine, 2025 Dec 09

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma.

Nature medicine, 2025 Feb 05

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.

Lancet (London, England), 2020 Apr 18

Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.

The New England journal of medicine, 2025 Dec 06

Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia.

ASH 2025

Questions discussed in this category

Papers discussed in this category

Related Topics